P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 389 000 KRW -0.89%
Market Cap: 4T KRW

PharmaResearch Co Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

PharmaResearch Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash from Operating Activities
â‚©149.5B
CAGR 3-Years
32%
CAGR 5-Years
45%
CAGR 10-Years
25%
Celltrion Inc
KRX:068270
Cash from Operating Activities
â‚©812.1B
CAGR 3-Years
42%
CAGR 5-Years
22%
CAGR 10-Years
34%
SK Bioscience Co Ltd
KRX:302440
Cash from Operating Activities
-â‚©128B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Cash from Operating Activities
-â‚©29.1B
CAGR 3-Years
-18%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash from Operating Activities
â‚©86.5B
CAGR 3-Years
N/A
CAGR 5-Years
74%
CAGR 10-Years
43%
A
ABL Bio Inc
KOSDAQ:298380
Cash from Operating Activities
-â‚©23.6B
CAGR 3-Years
18%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

PharmaResearch Co Ltd
Glance View

Market Cap
4T KRW
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.

PharmaResearch Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is PharmaResearch Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
149.5B KRW

Based on the financial report for Jun 30, 2025, PharmaResearch Co Ltd's Cash from Operating Activities amounts to 149.5B KRW.

What is PharmaResearch Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
25%

Over the last year, the Cash from Operating Activities growth was 43%. The average annual Cash from Operating Activities growth rates for PharmaResearch Co Ltd have been 32% over the past three years , 45% over the past five years , and 25% over the past ten years .

Back to Top